| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.05 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | -0.077 | 0.05 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.06 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.06 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.076 | 0.06 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |